Trials / Unknown
UnknownNCT05686629
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
A Study to Assess the Efficacy and Safety of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib hydrochloride tablets | 2 doses per day, each containing two 50mg Jaktinib or placebo tablets |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2025-02-01
- Completion
- 2025-03-01
- First posted
- 2023-01-17
- Last updated
- 2023-10-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05686629. Inclusion in this directory is not an endorsement.